In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

StemCells Finds White Knight In Microbot

Executive Summary

In May 2016, results from StemCell Inc.’s Phase II study of its only product still in development, a preparation of human neural stem cells for the treatment of chronic spinal cord injuries, suggested that there was little chance of the product ever becoming a commercial success. The company’s stock plummeted 80% overnight. Then, in August, when all appeared to be lost, StemCells announced that it was entering a strategic merger agreement with the Israeli company Microbot Medical Ltd., which researches and develops micro-robotic assisted medical technologies.

Advertisement

Topics

Related Companies

UsernamePublicRestriction

Register